In vivo, the infectious dose and viral source involved in transmission remain uncertain and it is likely that women will use microbicides both before and after high-risk HIV exposure. Therefore, we evaluated HIV entry inhibitors (EIs) and reverse transcriptase inhibitors (RTIs) for their ability to block cell-free and cell-associated HIV-1 infection in co-cultures of monocyte-derived dendritic cells (MO-DC) and CD4 + T-cells using settings of pre-and post-exposure prophylaxis. In the pre-exposure assay, where compound was present before, during and 24 h after infection, all tested EIs (BMS806, TAK779 and T20) and RTIs (PMPA, TMC120 and UC781) blocked infection with 10 -4 multiplicity of infection (MOI) of cell-free virus at a dose between 100 and 10,000 nM, dependent on the compound used. At 10 -3 MOI, however, only T20 and the RTIs completely blocked infection. Furthermore, in experiments with cell-associated virus, EIs were ineffective, whereas RTIs actively blocked infection with similar potency as in the experiments with cell-free virus. In the post-exposure assay, where compound was added 2 h after infection and remained present for 24 h, EIs were inactive whereas RTIs blocked cellfree and cell-associated viral infections equally efficiently. Moreover, post-exposure prophylaxis initiated 24 h after infection with cell-free or cellassociated HIV-1 was still effective with 1,000 nM of TMC120. Both EIs and RTIs were non-cytotoxic at any tested concentration for MO-DC and CD4 + T-cells in co-culture. Our study shows that RTIs are potent inhibitors of cell-free and cell-associated virus used either in pre-or post-exposure settings. It highlights that parameters such as viral input, viral source, the time of compound addition and the target cells should be considered in microbicides evaluation.
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Prevention of HIV/AIDS infection is critical in controlling the continuous spread of the pandemic. Heterosexual transmission is the principal mode of transmission and women are particularly affected (Quinn & Overbaugh, 2005; Madkan et al., 2006) . Globally, almost 50% of the HIVinfected population are women and the proportion is increasing over time, especially in young people (Quinn & Overbaugh, 2005) . Preventive interventions, such as microbicides under the control of women therefore represent a promising approach to limiting the spread of HIV (Keller et al., 2003; Van Damme, 2004; Balzarini & Van Damme, 2005; Smith et al., 2005; Dhawan & Mayer, 2006) .
The potential role of microbicides in pre-exposure settings is clearly recognized (Keller et al., 2003; Balzarini & Van Damme, 2005; Smith et al., 2005; Lederman et al., 2006) ; however, once freely available in the general population, microbicides will also be used after high-risk exposure. Consequently, it is necessary to evaluate the efficacy of candidate microbicides in both pre-and post-exposure settings. Since many first-generation broad-spectrum microbicides may lack potency or damage epithelia when used frequently (Keller et al., 2003; Van Damme, 2004; Balzarini & Van Damme, 2005; Madan et al., 2006) more specific anti-HIV entry inhibitors (EIs) and reverse transcriptase inhibitors (RTIs) are currently being studied as potentially more effective and safer alternatives (Shattock & Moore, 2003; Balzarini & Van Damme, 2005; Beer & Cummins, 2005; Dhawan & Mayer, 2006; Lederman et al., 2006; Madan et al., 2006) .
Infected semen and cervico-vaginal secretions contain cell-free viruses and viruses associated with monocytes, macrophages and T lymphocytes (Coombs et al., 2003; D'Cruz & Uckun, 2006; Lederman et al., 2006) , and both have been shown to be infectious (Coombs et al., 2003; Kaizu et al., 2006; Lederman et al., 2006) . Modelling sexual transmission in cervical tissue explants and in animals has shown that HIV rapidly associates with dendritic cells/T-cell clusters, which are crucial in the spread of virus to the regional lymph nodes and subsequent systemic dissemination (Masurier et al., 1998; Shattock & Moore, 2003; Veazey & Lackner, 2003; Maher et al., 2005; Dhawan & Mayer, 2006; Lederman et al., 2006; Gupta & Klasse, 2006) . Moreover, since physical or inflammation/infection-induced epithelial breaches are frequently associated with HIV transmission, it is important to test microbicides in vitro as if the virus has free access to mucosal DC and T cells.
Therefore, we used the previously described co-culture system of MO-DC and autologous CD4 + T-cells, which are representative of primary mucosal target cells involved in sexual HIV transmission (Van Herrewege et al., 2002) . In this system we evaluated the concept of microbicides by using prototype compounds targeting HIV binding, fusion and reverse transcription to determine their ability to block viral transmission under conditions of pre-and post-exposure prophylaxis against both cellfree and cell-associated HIV. In addition, as a reference of antiviral activity, HIV inhibitors were tested using an in vitro cell line-based assay with single-cycle infectious pseudovirus, and the compounds' toxicity in the MO-DC/CD4 + T-cell co-culture system was evaluated by WST-1 tetrazolium-based assay.
Materials and methods
Cell line and primary cells
Green fluorescent human osteosarcoma cells expressing CD4 and CCR5 (GHOST-R5) were grown in DMEM (BioWhittaker, Verviers, Belgium), containing puromycin (1 μg/ml) (Sigma-Aldrich, Bornem, Belgium), hygromycin B (50 μg/ml) (Roche, Mannheim, Germany), penicillin (100 U/ml), streptomycin (100 μg/ml), geneticin (500 μg/ml) (Invitrogen, Paisley, Scotland) and fetal calf serum (FCS) (10%) (Biochrom AG, Berlin, Germany), in continuous culture at 37˚C, 5% CO 2 and humidified atmosphere, and sub-passaged every 3 to 4 days.
MO-DC and CD4 + T-lymphocytes were obtained from buffy coats from healthy donors, (kindly provided by the Antwerp Blood Transfusion Centre, Antwerp, Belgium) as previously described (Van Herrewege et al., 2002; Njai et al., 2005) . For some experiments, peripheral blood mononuclear cells (PBMCs) were activated by culture in complete medium (RPMI-1640 [BioWhittaker] containing 10% FCS and gentamycin [50 mg/ml; BioWhittaker]) supplemented with phytohaemagglutinin (PHA; 2 μg/ml for 48 h; Remel, Kent, UK) and subsequently interleukin-2 (IL-2; 1 ng/ml for 24 h; Gentaur, Brussels, Belgium).
Single-cycle infectious pseudovirus and replication-competent virus
The single-cycle infectious HIV-1 pseudovirus (PV) expressing Ba-L env was used in the GHOST-R5 cellbased assay. PV was prepared in 293 T cells by co-transfection of the cells with the HIV-1 reporter construct pNL4-3.Luc.R-E under the LTR promoter (which contains the whole HIV genome, including a packaging signal, but with a frameshift in the env and vpr genes rendering it nonreplicative while the luciferase gene replaces the nef gene) and the HIV-1 Ba-L envelope-expressing construct pcDNA4/TO under CMV promoter (NIH AIDS Reference Reagent Program, Rockville, MD, USA). Cotransfection was done using the calcium phosphate method (Pro Fection mammalian transfection system; Promega, Leiden, the Netherlands) according to the manufacturer's protocol. At 24 h of culture, medium containing 1 mM sodium butyrate (Sigma-Aldrich) was added and after an additional 24 h, supernatants were collected and passed through a 0.45 μm pore-size filter. The infectious titre of the PV Ba-L env stock was determined using GHOST-R5 cells, which were lysed 48 h post-infection by addition of the luciferin substrate (SteadyLite HTS; PerkinElmer Life Sciences, Zaventem, Belgium). The resulting light signal expressed as relative light units per second (RLU) was quantified using a luminometer (Top Count™; CamberraPackard, Zellik, Belgium).
For infection of MO-DC/CD4 + T-cell cultures, we used HIV-1 subtype B, non-syncytium inducing, CCR5-using reference Ba-L strain (NIH AIDS Reference Reagent Program). Cell-free virus stocks were prepared in PHA/IL-2 activated PBMCs and quantified by p24 antigen measurement. To prepare cell-associated virus, freshly obtained non-stimulated PBMCs were incubated overnight with cell-free Ba-L at 10 -2 multiplicity of infection (MOI). After extensive washing, the HIV-infected cells (hereafter referred to as HIV-PBMC) were frozen and stored in liquid nitrogen until use. To determine the infectivity in our model system, several MOIs of cell-free virus to MO-DC or different proportions of HIV-PBMC and MO-DC were incubated for 2 h, washed and co-cultured with autologous CD4 + T-cells for 14 days. Supernatants were then analysed for p24 production.
Reference compounds used in this study included the CD4-gp120 binding inhibitor BMS806, the CCR5 antagonist TAK779, the gp41 fusion inhibitor T20 (NIH AIDS Research and Reference Reagent Program), the nucleotide RTI (NtRTI) PMPA (kindly provided by Prof J Balzarini, Rega Institute, Leuven, Belgium) as well as the non-nucleoside RTIs (NNRTIs) TMC120 (R147681, dapivirine; kindly provided by Tibotec BVBA, Mechelen, Belgium) and UC781 (kindly provided by Prof J Balzarini). Compound stocks were prepared by dissolution in DMSO (BMS806, TMC120 and UC781) or in phosphate buffered saline (PBS; BioWhittaker; TAK779, T20 and PMPA) at 10 or 100 mM, and used to make a 10-fold dilution series. All compounds were used at non-toxic concentrations as determined by the WST-1-tetrazolium based assay.
Compound activity in a single-cycle infectious pseudovirus assay A quantity of 50 μl of PV (200,000 RLU) was pre-incubated with 50 μl of a dilution range of compound in triplicate, in 96 black-well/transparent-bottom plates (Greiner; BioOne GMBH, Frickenhausen, Germany). After 30 min at 37°C, 100 μl of GHOST-R5 cells (1.2×10 5 /ml) were added and incubated for 48 h at 37°C in the presence of compound. Afterwards, cells were lysed in the luciferin substrate-containing buffer and the resulting light signal was quantified in a luminometer. The compound-mediated inhibition of infection expressed as percentage of untreated controls was plotted against compound concentration, and linear regression analysis was applied to determine the 50% effective concentration (EC 50 ).
Evaluation of pre-exposure prophylaxis in MO-DC/CD4 + T-cell co-cultures A quantity of 50 μl of cell-free virus at 10 -4 or 10 -3 MOI, or 0.2×10 6 HIV-PBMC was pre-incubated with 50 μl of complete medium or 50 μl of a 10-fold serial dilution of compound (each one in six replicates in 96-well plates) for 30 min at 37°C, 5% CO 2 and saturated humidity. Next, 100 μl of MO-DC (0.2×10 6 /ml) were added and incubated for 2 h. Cultures were thoroughly washed with medium and subsequently co-cultured with 100 μl of CD4 + T-cells (1×10 6 /ml) and 100 μl of corresponding compound concentration. After 24 h, cells were washed again and cultured for 14 days in complete medium without compound. At day 14, supernatant was removed and replaced by 200 μl of activated PBMCs (5×10 5 /ml) to detect latent or subliminal infection (viral rescue) ( Figure 1A ). After an additional incubation for 7 days, 100 μl of supernatant was analysed for HIV-1 p24 antigen.
Evaluation of post-exposure prophylaxis in MO-DC/CD4
+ T-cell co-cultures MO-DC (0.2×10 6 /ml; 100 μl) were incubated with 100 μl of cell-free virus (10 -4 or 10 -3 MOI) or cell-associated virus (0.2×10 6 /ml) for 2 h, and washed and co-cultured with 100 μl of CD4 + T-cells (1×10 6 /ml) for 2 h. At this time point, 100 μl of complete medium or compound was added and cultured for 24 h. Afterwards, the cultures were washed and continued as mentioned above in the absence of compound ( Figure 1B) .
Evaluation of the window of efficacy in post-exposure prophylaxis of MO-DC/CD4 + T-cell co-cultures MO-DC (0.2×10 6 /ml; 100 μl) were incubated with 100 μl of cell-free virus (10 -3 MOI) or cell-associated virus (0.2×10 6 /ml) for 2 h, and washed and co-cultured with 100 μl of CD4 + T-cells (1×10 6 /ml) for 2, 4, 6, 18 or 24 h. At each of these time points, 100 μl of complete medium or compound was added and the MO-DC/CD4 + T-cell cocultures were subsequently incubated for 24 h, after which they were washed and continued as mentioned above in the absence of compound.
Evaluation of viral replication and compoundmediated inhibition of infection in MO-DC/CD4 + T-cell co-cultures
Viral replication in MO-DC/CD4
+ T-cell co-cultures was evaluated by p24 HIV-1 antigen detection in supernatants using an in-house capture ELISA as previously described (Beinaert et al., 1998) . Only data after 21 days of culture are represented (14 days of MO-DC/CD4 + T-cell cocultures and 7 days of viral rescue with activated PBMCs). Results are expressed as the percentage of inhibition of viral replication in reference to infected but untreated cultures. In the pre-exposure setting, the mean of four or more independent experiments is represented for BMS806, TAK779, T20 and TMC120 and a single experiment for PMPA and UC781. In the post-exposure setting, the mean of at least two independent experiments is represented in the assays with cell-free virus (except BMS806, PMPA and UC781, where a single experiment is reported) and cell-associated virus. Compound concentration required to reduce HIV antigen production by 50% (EC 50 ) was calculated by linear regression analysis of p24 concentration as a function of the compound concentration, and reported as geometric mean of respective experiments where applicable.
Evaluation of compound toxicity in the MO-DC/ CD4 + T-cell co-culture model
Co-cultures of MO-DC at 0.4×10 6 /ml (50 μl) and CD4 + T-cells at 2×10 6 /ml (50 μl) were incubated with 100 μl of complete medium or a 10-fold serial dilution of compound (each one in six replicates in 96-well plates) for 24 h at 37°C, 5% CO 2 and saturated humidity. Afterwards, cells were carefully washed and incubated either with WST-1 tetrazolium salt for 4 h according to manufacturer's protocol (Roche Diagnostic, Mannheim, Germany; acute toxicity) or with 200 μl of complete medium for additional 3 days and then with WST-1 tetrazolium salt (delayed toxicity). The resulting soluble formazan product was quantified using a microplate reader (BioRad, Tokyo, Japan) at 450 nm and the percentage of viable cells was calculated in reference to untreated controls.
Results
Entry and RT inhibitors exhibit efficient anti-HIV activity in a single-cycle infectious pseudovirus assay
All reference HIV-1 inhibitors potently inhibit Ba-L PV infection of GHOST-R5 cells, with EC 50 values in the low nanomolar range. The EIs BMS806, TAK779 and T20 and the RTIs PMPA, TMC120 and UC781 showed EC 50 values of 5, 42, 55, 82, 2 and 5 nM, respectively, which were consistent with previous reports (Veazey et al., 2005; Maeda et al., 2004; Van Herrewege et al., 2004b; Aquaro et al., 2006; Zhang et al., 2006) . + T-cells. In both pre-and post-exposure prophylaxis settings, compound remained present for 24 h. Next, the cultures were washed and subsequently incubated without compound. At day 14, subliminal or latent infection was revealed by addition of activated peripheral blood mononuclear cells (PBMCs). Supernatants were collected 7 days later and p24 HIV antigen (p24 Ag) was detected by ELISA. IL-2, interleukin-2; PHA, phytohaemagglutinin. 
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In settings of pre-exposure prophylaxis, the antiviral activity of EIs is highly dependent on the viral input and viral source, whereas RTIs remain consistently active.
HIV-1 EIs and RTIs were evaluated for their capacity to block viral infection in a physiologically relevant model of primary MO-DC and CD4 + T-cell co-cultures. In this in vitro system, we used replication-competent cell-free or cell-associated HIV-1 in both pre-and post-exposure settings. Preliminary experiments (data not shown) using 10 -4 , 10 -3 or 10 -2 MOI of cell-free Ba-L on one hand or 1:10, 1:5, 1:3, 1:1 and 2:1 ratios of cell-associated HIV-PBMC to MO-DC on the other, indicated that the optimum minimal infectious dose for reproducible infection of MO-DC/CD4 + T-cell co-cultures was 10 -4 MOI of cell-free Ba-L and a 1:1 ratio of HIV-PBMC to MO-DC in the cell-associated set-up. Because we wanted to exclude subliminal infection in the co-cultures, we considered only inhibition of viral replication at the end of the additional rescue culture (see Figure 1 ).
Compounds were pre-incubated with the virus and remained present during the first 24 h of the co-culture of MO-DC and autologous CD4 + T-cells (this set-up represents an early single application of microbicides and the presumed wash-out period in vivo). At a low cell-free virus dose (10 -4 MOI), BMS806 and T20 blocked infection at a concentration of 1,000 nM, while TAK-779 had blocking activity at 10,000 nM. The NtRTI PMPA and the NNRTI TMC120 blocked infection at 100 nM, whereas the NNRTI UC781 completely protected against infection at 1,000 nM. At a 10 times higher viral input (10 -3 MOI), complete viral blocking was attained by 10,000 nM of T20 but could not be achieved by the same concentration of BMS806 or TAK779. Moreover, 1,000 nM of PMPA or UC781 and 100 nM of TMC120 were sufficient to block infection (Figure 2A,B) . The EC 50 values of EIs in experiments using cell-free virus ranged from 40 to 3,105 nM; in comparison EC 50 values of RTIs ranged from 2 to 316 nM (Table 1) .
It could be argued that TAK779 acts at the target cells and not on the virus. Therefore, a second set of experiment was carried out in which the compound was pre-incubated for 30 min with MO-DCs before infection and remained present during and after infection for 24 h. Results from a single donor showed no major difference in efficacy; the EC 50 values against 10 -4 and 10 -3 MOI of virus were 785 and 5,863 nM, respectively, versus 218 and 3,105 nM in the setting where the virus was pre-incubated with TAK779 (Table 1) .
When HIV-PBMC was used (1:1 ratio), none of the EIs could prevent viral infection, even at the highest concentration tested (10,000 nM; Figure 2A and Table 1 ). In contrast, PMPA efficiently blocked cell-associated viral infection at 10,000 nM, whereas 100 nM of TMC120 or 1,000 nM of UC781 sufficed for blocking ( Figure 2B ). The EC 50 values for these three RTIs ranged from 3 to 130 nM (Table 1) .
Furthermore, the antiviral activity of EIs and RTIs against the R5 virus Ba-L, with a limited 24 h of treatment of MO-DC/CD4 + T-cell co-cultures infected with low concentration of cell-free virus, are in a similar range of EC 50 values as compared with the values obtained with standard PBMC cultures where compounds are continuously present. The most notable exception, however, is PMPA: the NtRTI showed a more potent activity on MO-DC/CD4 + T-cell co-cultures as compared with PBMC ( Table 2 ).
In settings of post-exposure prophylaxis, only RTIs can efficiently block both cell-free and cellassociated virus infection
To mimic the in vivo situation where a microbicide might be used after potential risk exposure, an in vitro setting for post-exposure prophylaxis was developed. In these experiments, compound was added 2 h after infection of the MO-DCs and subsequent co-culture with CD4 + T-cells (see Figure 1B) . EIs showed no inhibitory activity, independent of the viral input and whether cellfree or cell-associated HIV was used ( Figure 3A and Table 1 ). In contrast, in experiments using cell-free virus at a 10 -4 MOI, RTIs blocked infection at a concentration of 100 nM of PMPA or TMC120 or 1,000 nM of UC781. At a 10 -3 MOI viral input, blocking concentrations increased to 10,000 nM for PMPA and UC781, but remained unaffected at 100 nM for TMC120. Experiments with cell-associated virus showed that 99% of HIV blocking activity could be achieved with PMPA at 10,000 nM and complete protection was achieved with TMC120 and UC781 at 1,000 nM ( Figure 3B ). The RTIs showed consistent antiviral activity against either cell-free or cell-associated virus, with EC 50 values similar to the values obtained in the setting of pre-exposure prophylaxis (Table 1) .
Extended post-exposure prophylaxis efficacy of TMC120 against cell-free and cell-associated HIV infection of MO-DC/CD4 + T-cell cultures
The three RTIs included in our study could prevent infection of MO-DC/CD4 + T-cell co-culture, irrespective of whether compounds were used in pre-or post-exposure prophylaxis with cell-free or cell-associated virus. Among the three RTIs, the NNRTI TMC120 was the most potent one. In order to define the 'window of opportunity' we added TMC120 at different time points after viral exposure. Using cell-free HIV at 10 -3 MOI, TMC120 efficiently blocked infection at 100 nM. This blocking activity was maintained in settings where the compound was added up to 6 h after co-culture of the infected MO-DC with CD4 + T-cells. If the addition of TMC120 was further postponed to 24 h after infection, the potency decreased and 100 nM of TMC120 could only inhibit 17% of viral replication, but addition of 1,000 nM of TMC120 still completely blocked infection ( Figure 4A ). Similarly, infections by cellassociated HIV were consistently blocked using 1,000 nM of TMC120 added up to 24 h after infection ( Figure 4B ).
Toxicity of entry and RTIs in the MO-DC/CD4 + T-cell co-cultures
Acute direct cytotoxic effect or the possibility of a delayed toxic effect of HIV-1 inhibitors in the MO-DC/CD4 + Tcell co-cultures was evaluated by the WST-1-tetrazoliumbased reduction assay. Compounds were tested to a maximal concentration of 10,000 nM, corresponding to the 
B A
maximum that we could use to avoid toxicity by the stock solvent DMSO (minimum dilution factor 1:100; data not shown). No toxic effect was observed at any compound concentration tested. Cell viability was above 90% for both the acute cytotoxicity assay, where compound was incubated with cells for 24 h, and the delayed toxicity assay, where cells were further incubated for additional 3 days after discarding the compound to detect possible delayed negative effect. Therefore the 50% cytotoxic concentration (CC 50 ) for all compounds was >10,000 nM.
Discussion
Microbicides represent one hope to slow down the continuous growth of the HIV epidemic, which is predominantly driven by heterosexual transmission. Several elements are essential to select products for in vivo microbicide studies, including lack of toxicity, ease of formulation, affordability and acceptability (Derdelinckx et al., 2006) . The primary criterion, however, should be a potent and consistent anti-HIV activity under various circumstances.
In principle, microbicides should be applied before high-risk exposure and therefore the antiviral activity of compounds in settings of pre-exposure prophylaxis is currently being evaluated in several in vitro (Zussman et al., 2003; Hu et al., 2004; Van Herrewege et al., 2004a,b; Njai et al., 2005; Fletcher et al., 2005 Fletcher et al., , 2006 Lu et al., 2006) and in vivo studies (Tsai et al., 1995; Di Fabio et al., 2003; Veazey et al., 2003a,b; Veazey et al., 2005; Subbaro et al., 2006) . It is, however, very likely that microbicides will also Pre-exposure prophylaxis: HIV-1 BaL virus was pre-incubated with compound which remained present during infection of the monocyte-derived dendritic cells (MO-DC) and 24 h after initiation of the MO-DC/CD4 + T-cell co-culture (see Figure 1A ). Post-exposure prophylaxis: compound was added 2 h after infection of the MO-DC and the subsequent co-culture with CD4 + T-cells and remained present for 24 h (see Figure 1B ). Linear regression analysis was used to calculate 50% effective compound concentrations (EC 50 ). In the pre-exposure setting, values represent the geometric mean and range of at least four independent experiments with entry inhibitors and TMC120 using cell-free virus and at least two independent experiments using cell-associated virus. A single experiment is reported for PMPA and UC781 for both cell-free and cellassociated HIV-1 infections. In the post-exposure setting, values represent the geometric mean and range of at least two independent experiments for TAK779, T20 and TMC120. A single experiment is reported for BMS806, PMPA and UC781 for both cell-free and cell-associated virus settings. In all experiments, each data point relies on six replicates. MOI, multiplicity of infection. Previous studies using the HIV-1 inhibitors continuously present in peripheral blood mononuclear cell (PBMC) cultures against infection with ‡ SHIV-162P3 virus (Veazey et al., 2003) ; § Ba-L virus (Maeda et al., 2004) ; ¶ HIV IIIB virus (Zhang et al., 2006) ; # Ba-L virus (Van Herrewege et al., 2002) ; EC 50 , 50% effective compound concentration; MOI, multiplicity of infection; NF, not found. be used after a possible risk exposure. The proven success of post-exposure treatments to prevent occupationalrelated transmission or mother-to-child transmission indicates that HIV infection can still be blocked soon after exposure (Moodley et al., 2003; Pozniak, 2004; Gupta & Klasse, 2006; Shapiro et al., 2006) ; but it is less sure if preventive drugs are still active after HIV sexual exposure. Therefore, microbicide candidates need to be evaluated in both pre-and post-exposuse prophylaxis settings using physiologically relevant models for sexual HIV transmission.
We evaluated a set of reference HIV-1 inhibitors using an in vitro co-culture model of autologous MO-DC and CD4 + T-cells, representative of primary target cells in 
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sexual HIV transmission (Masurier et al., 1998; Shattock & Moore, 2003; Veazey & Lackner, 2003; Balzarini & Van Damme, 2005; Dhawan & Mayer, 2006; Lederman et al., 2006) . We show here that this model can be adapted to mimic infection by both cell-free and cell-associated HIV in either a pre-or post-exposure setting. Because HIV mucosal transmission is strongly associated with CCR5 coreceptor using isolates (Shattock & Moore, 2003; Balzarini & Van Damme, 2005; Dhawan & Mayer, 2006) we focussed on the reference subtype B HIV-1, CCR5 coreceptor using strain Ba-L. Initially, as a first screening we used the single-cycle infectious pseudovirus assay. In this assay all entry and RTIs displayed similarly potent antiviral activity in the nanomolar range. In contrast, using the MO-DC/CD4
+ T-cells model, our results highlight that compounds from several classes of anti-HIV activity may be effective in one set of conditions (for example, pre-exposure inhibition of low-dose cell-free virus), whereas they show less activity under other circumstances. Clearly, under the stringent condition in which treatment is limited to 24 h, entry inhibitors were effective at preventing infection by cell-free virus, but were less active in other conditions: for example, both binding and fusion inhibitors failed against cell-associated virus in pre-exposure and against both cell-free and cell-associated virus in the post-exposure condition. Obviously, a decreased antiviral efficiency of attachment and fusion inhibitors can be expected in post-exposure setting. Nevertheless, this class of compounds was previously shown to prevent cell-free virus infection in cervical tissue (Hu et al., 2004) and macaques (Veazey et al., 2003a (Veazey et al., , 2003b (Veazey et al., , 2005 and some binding inhibitors were active against cell-associated virus at high concentrations (Lu et al., 2006) . Therefore, although binding/fusion inhibitors alone may be insufficient as single microbicides, they could make a valuable contribution to a combination microbicide strategy to protect non-infected target cells (Liu et al., 2005; Veazey et al., 2005; Sterjovski et al., 2006; Zhang et al., 2006) .
The three RTIs evaluated showed a consistent activity against both cell-free and cell-associated HIV-1 and in both pre-and post-exposure settings. The observed potent activity of PMPA, an NtRTI, to block infection driven by cell-free virus is consistent with earlier reports (Van Herrewege et al., 2002; Fletcher et al., 2006) . In addition we show here its blocking activity of infections driven by cell-associated virus. Moreover, in line with studies in the macaque model where compound and virus challenge were used systemically (Tsai et al., 1995 (Tsai et al., ,1998 or where compound was given systemically and virus challenge was delivered intravaginally (Otten et al., 2000) , we show here that using the MO-DC/CD4 + T-cell co-culture model that mimics the possible use of microbicide, PMPA was efficient in blocking viral replication in both pre-and postexposure prophylaxis settings. The NtRTI PMPA showed a more potent antiviral activity in the MO-DC/CD4 + Tcell system as compared with reported studies using PBMCs. This unexplained observation further supports, at first sight, the development of PMPA as a microbicide.
Our pre-exposure prophylaxis results for both UC781 and TMC120 against cell-free and/or cell-associated virus correlate with those previously reported from our laboratory and others in which cellular assays (Zussman et al., 2003; Van Herrewege et al., 2004b; Njai et al., 2005) ; tissue explants (Fletcher et al., 2005) or a SCID mice model were used (Di Fabio et al., 2003) . Furthermore, we also demonstrate with these chemically unrelated NNRTIs that a limited 24 h of treatment, either in pre-or post-exposure 
settings, was sufficient to completely block viral infection and protect cells against both cell-free and cell-associated virus challenge. Moreover, our data indicate that postexposure prophylaxis with TMC120 up to 24 h after infection was still possible therefore providing a window of opportunity for delayed intervention.
Safety is paramount in prevention settings of sexual HIV transmission; we report here that all compounds, at concentrations used, have no toxic activity in the MO-DC/CD4 + T-cell co-culture system; however, cells were exposed to compound for a limited period of 24 h according to our experimental conditions.
In conclusion, we argue that in vitro evaluation of candidate microbicides should mimic the complexity of transmission, including the use of physiologically relevant primary targets cells and both cell-free and cell-associated virus. Additionally, we provide evidence that both settings of pre-and post-exposure prophylaxis are of importance in selecting the most promising candidate microbicides.
